Impact of antiarrhythmic drugs on the outcome of short QT syndrome

• Verfasst von: El-Battrawy, Ibrahim [VerfasserIn]
• Verfasst von: Besler, Johanna [VerfasserIn]
• Verfasst von: Li, Xin [VerfasserIn]
• Verfasst von: Lan, Huan [VerfasserIn]
• Verfasst von: Zhao, Zhihan [VerfasserIn]
• Verfasst von: Liebe, Volker [VerfasserIn]
• Verfasst von: Schimpf, Rainer [VerfasserIn]
• Verfasst von: Lang, Siegfried [VerfasserIn]
• Verfasst von: Wolpert, Christian [VerfasserIn]
• Verfasst von: Zhou, Xiao-Bo [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Verfasst von: Borggrefe, Martin [VerfasserIn]
• Titel: Impact of antiarrhythmic drugs on the outcome of short QT syndrome
• Verf.angabe: Ibrahim El-Battrawy, Johanna Besler, Xin Li, Huan Lan, Zhihan Zhao, Volker Liebe, Rainer Schimpf, Siegfried Lang, Christian Wolpert, Xiaobo Zhou, Ibrahim Akin and Martin Borggrefe
• E-Jahr: 2019
• Jahr: 02 August 2019
• Fussnoten: Gesehen am 11.10.2019
• Titel Quelle: Enthalten in: Frontiers in pharmacology
• Ort Quelle: Lausanne : Frontiers Media, 2010
• Jahr Quelle: 2019
• Band/Heft Quelle: 10(2019) Artikel-Nummer 771, 10 Seiten
• ISSN Quelle: 1663-9812
• DOI: doi:10.3389/fphar.2019.00771
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: arrhythmia
• Sach-SW: channelopathy
• Sach-SW: congenital disease
• Sach-SW: short QT syndrome
• Sach-SW: Sudden cardiac arrest
• K10plus-PPN: 167878494X
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Abstract: Short QT Syndrome (SQTS) is associated with sudden cardiac arrest (SCA). There is limited data on the impact of antiarrhythmic drugs on the outcome of SQTS. Material and Methods: We studied data describing the clinical outcome of 62 SQTS patients treated with antiarrhythmic drugs, recruited from a pool of patients diagnosed in our institution and also from known databases after a systematic search of published literature. Results: 62 SQTS patients treated with anti-arrhythmic drugs were followed up over a median timeframe of 5.6 years (1.3-4.1 years). 6 patients in particular, received multiple drugs as a combination. Out of 55 patients treated with hydroquinidine (HQ) the long-term prophylaxis was documented in 41 patients. 14 patients stopped the treatment for the following reasons: gastrointestinal intolerance (n=4), poor compliance (n=8), and no QTc prolongation (n=2). Of the 41 patients with HQ the QTc interval increased from 313.5±17.2 ms to 380.1±21.2 ms. 13/41 of the patients suffered at least 1 or more ventricular arrhythmia (VA) before HQ initiation. VAs are reduced in incidence after HQ treatment (13/41: 31% versus 3/41: 7.3%, p<0.001). Conclusion: HQ increases the corrected QT interval and prevents VAs in the majority of patients in this cohort. HQ is safe for use in SQTS patients particularly with its low rate of side effects. Other antiarrhythmic drugs might be useful, but the data justifying their use are sparse.